Multispecific antibodies are increasingly being explored in the pharmaceutical industry for unmet patient needs, reshaping therapeutic possibilities by targeting multiple disease pathways simultaneously. Since the approval of the first bispecific antibody, Blincyto, this field has grown into a multibillion-dollar market, with global sales surpassing USD 12 billion in 2024 and projected to exceed USD 50 billion by 2030.
As of May 2025, 18 multispecific antibodies have gained regulatory approval worldwide, ranging from oncology breakthroughs such as Rybrevant (the first bispecific antibody for a solid tumor) to Hemlibra (a milestone in non-cancer indications). With more than 700 candidates currently in clinical trials and ongoing regulatory momentum across the US, EU, and Asia, the multispecific antibody landscape is both competitive and rapidly expanding.
However, traditional workflows, where bispecific conversion occurs late in the discovery pipeline, or where production involves complex and low-yield processes, are increasingly recognized as bottlenecks. To overcome these hurdles, researchers are developing new platforms that expand discovery capacity, streamline production, and even reimagine antibody design altogether.
A major limitation of bispecific antibody (bsAb) campaigns has been the late introduction of bispecificity, often at the end of the discovery process and in small numbers. A recent review highlights combinatorial matrix approaches that allow larger panels of bispecifics to be generated and screened at early discovery stages. By facilitating bi-target validation earlier, these platforms broaden the accessible protein space and maximize the likelihood of identifying successful candidates.
On the other hand, even when promising constructs are identified, not all formats are equally translatable. A systematic analysis of 64 antibody constructs targeting TNF provides a comparative developability profile across different molecular families, including bispecifics and antibody fragments. The study revealed that natural full-length IgGs maintain superior stability, while more complex engineered constructs showed higher risks of aggregation and fragmentation. Such insights emphasize the importance of developability profiling early in discovery to avoid costly failures downstream.
➡️ Together, these studies suggest that future discovery platforms will not only need to expand the pool of candidates but also build in early checks for manufacturability and stability, ensuring that promising molecules can move smoothly into later development.
Manufacturing electrostatic-steering multispecifics has traditionally required complex operations. Another recent study presents a novel column-based redox method that simplifies production: parental antibodies are bound to a protein A resin, reduced, eluted, and oxidized in a streamlined workflow to form heterodimers. Demonstrated across five diverse multispecifics, this approach reduces processing steps while preserving product quality and yield, offering a viable path toward industrial-scale implementation.
To simplify multifunctional antibody assembly, this research study introduces a modular platform using specific protein–protein interactions combined with elastin-like polypeptides (ELPs) for straightforward purification. The system produced multifunctional antibodies with over 90% assembly efficiency and broad applications, from cancer detection to T-cell engagement. Its modularity and robustness position it as a versatile tool for designing next-generation multispecifics with tailored functionality.
➡️ These advances illustrate how the manufacturing bottleneck is beginning to ease, with new methods offering both scalability and flexibility. But innovation is not limited to improving existing antibody workflows, as researchers are also exploring hybrid strategies that merge antibodies with entirely new scaffolding systems.
Meanwhile, researchers have also created multi-specific nano-antibodies (multi-NanoAbs) using a fusion protein/polymer-based adaptor system. Instead of chemical conjugation, antibodies are immobilized via receptor–ligand interactions with FcγR1, streamlining fabrication and maintaining affinity. Large-scale production was achieved, and preclinical models demonstrated potent antitumor effects. This work underscores the potential of hybrid nanomedicine approaches to emulate and even expand upon multispecific antibody functions.
Complementing experimental advances, another review surveys the landscape of post-translational assembly strategies, including chemical conjugation, oligonucleotide-mediated assembly, and SpyTag/SpyCatcher protein-protein interactions. Each method offers trade-offs in flexibility, specificity, and scalability, but collectively they highlight the field’s growing toolbox for assembling antibodies with diverse structures and functions.
➡️ Together, these studies reflect a shift toward a more versatile and adaptive future for multispecifics: one where traditional antibody formats can be augmented, or even reimagined, using modular and hybrid platforms.
From combinatorial discovery matrices to redox-based bioprocesses, nano-adaptors, and modular assembly frameworks, platform innovation is rapidly broadening what multispecific antibodies can achieve. The studies reviewed here highlight a three-pillar progression:
Expanding discovery capacity and integrating developability checks early,
Simplifying manufacturing with scalable, modular processes, and
Pioneering hybrid and post-translational strategies for greater flexibility.
As multispecific antibodies move deeper into oncology, autoimmune, and neurological indications, these platform advances will be crucial for ensuring that innovation translates into accessible, manufacturable therapies. The future of multispecifics will not be defined by a single format, but by the versatility of the platforms that support them.
Biointron’s bispecific antibody production will provide you high-quality bispecific antibodies in 3 to 4 weeks. We support the expression of all bispecific formats including but not limited to: Knobs-into-holes IgG, IgG-scFv fusion, CrossMab, Y-body, Bispecific T-cell Engagers (BiTEs), and more. We utilize mammalian cell systems, such as CHO-K1 and HEK293 for antibody expression, ensuring high yield and quality. Contact us at info@biointron.com to speak to an expert!
Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends……
Fusion proteins are engineered molecules combining domains from two or more dist……
Antibody-drug conjugates (ADCs) rely critically on the chemical linker as the m……
Despite comprising the largest family of druggable membrane proteins, only three……
You can also contact us on the Scientist and Science Exchange marketplaces.
